Compass Pathways ($CMPS) released an interim readout from their Phase 3 trial of Psilocybin (COMP360) for treatment resistant depression (TRD).
The data was positive and highly anticipated by the psychedelic community, but the stock dropped 50% on June 23rd. Brom Rector and Sam Tabone of XEIA Venture Partners react and comment in this emergency podcast.
We discuss:
0:00 - what did the Compass Pathways data readout actually say
12:00 - putting the Compass trial results into context vs SSRIs, Lexapro, Spravato and Ketamine
19:00 - why Compass crashed
24:00 - will Comp360 get FDA approval?
26:00 - will COMP360 be commercially successful?
30:00 - price targets for Compass Pathways $CMPS
35:00 - will Compass get acquired?
40:00 - are we bullish or bearish on Compass?
Stay up to date on Human 3 - the new epoch of health, wellbeing and performance